检索结果-南通市图书馆

Chinese expert consensus on the non-invasive imaging examination pathways of stable coronary artery disease

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Journal of Geriatric Cardiology 2018年第1期15卷 30-40页

作者： Yun-Dai CHEN Wei-Yi FANG Ji-Yan CHEN Zhan-Ming FAN Chuan-Yu GAO jun-Bo GE Zuo-Xiang HE Yong HUO Lang li Si-Jin li Xi-lie lu bin LV Ju-Ying QIAN Ya-jun SHI Zhu-jun SHEN Jing WANG Yi-ning WANG Lei XU li yang Bo YU Mei zhang jun-jie yang Shu-yang zhang Xiao-li zhang Shi-hua zhao yang ZHENG Yu-Chi HAN guang ZHI Chinese PLA General Hospital Beijing China Shanghai Chest Hospital Shanghai Jiaotong University Shanghai China guangdong General Hospital Guangzhou China Beijing Anzhen Hospital Capital Medical University Beijing China Henan Provincial People's Hospital Zhengzhou China Zhongshan Hospital Fudan University Shanghai China Fuwai Hospital Chinese Academy of Medical Sciences Beijing China The First Hospital of Peking University Beijing China The First Affiliated Hospital of guangxi Medical University Nanning China The First Affiliated Hospital of Shanxi Medical University Taiyuan China Peking Union Medical College Hospital Beijing China The 2^nd Affiliated Hospital of Harbin Medical University Harbin China Qilu Hospital of Shandong University Jinan China The First Bethune Hospital of Jilin University Changchun China University of Pennsylvania United States

1 Introduction Early detection and diagnosis of stable coronary artery disease （SCAD） is essential for proactive secondary prevention of myocardial infarction （MI）, control of disease progress, and reduction of mortality. Clinical decision-making in modem medicine is increasingly dependent on cardiovascular imaging techniques. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease has been issued by American Heart Association （AHA）. European Society of Cardiology （ESC） has issued 2013 ESC guidelines on the management of stable coronary artery disease.

关键词： Expert consensus Clinical pathway Coronary artery disease Non-invasive imaging examination Pre-test probabilities

Study of the response of 10B-doped MCP to wide-energy range neutrons from eV to MeV

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Nuclear Science and Techniques 2024年第8期35卷 132-141页

作者： Qiang li li‑Jiao Wang Xiang‑Biao Qiu Jing‑Wen li Wei Xu Tao li Ze‑bin lin Chang‑jun ning Yong‑Hao Chen Rui‑Rui Fan Kang Sun Jing‑Yu Tang Rong zhang Han‑Tao Jing Bo Mei Qi An Hao‑Fan Bai Jiang‑Bo Bai jie Bao Ping Cao Qi‑Ping Chen Zhen Chen Zeng‑Qi Cui An‑Chuan Fan Chang‑Qing Feng Fan‑Zhen Feng Ke‑Qing Gao Min‑Hao Gu Chang‑Cai Han Zi‑jie Han Guo‑Zhu He Yong‑Cheng He yang Hong Yi‑Wei Hu Han‑Xiong huang Wei‑hua Jia Hao‑Yu Jiang Wei Jiang Zhi‑jie Jiang Zheng‑Yao Jin ling Kang Bo li Chao li Gong li Jia‑Wen li Xiao li yang li jie liu Rong liu Shu‑bin liu guang‑Yuan luan bin‑bin Qi jie Ren Zhi‑Zhou Ren Xi‑Chao Ruan zhao‑Hui Song Zhi‑Xin Tan Sheng‑Da Tang Peng‑Cheng Wang zhao‑Hui Wang Zhong‑Wei Wen Xiao‑guang Wu Xuan Wu li‑Kun Xie Yi‑Wei yang Han Yi Yong‑Ji Yu Guo‑Hui zhang lin‑Hao zhang Mo‑Han zhang Qi‑Wei zhang Xian‑Peng zhang Yu‑liang zhang Yue zhang Zhi‑Yong zhang Mao‑Yuan zhao lu‑Ping Zhou Zhi‑Hao Zhou Ke‑jun Zhu Institute of High Energy Physics Chinese Academy of Sciences(CAS)Beijing 100049China Spallation Neutron Source Science Center Dongguan 523803China State Key Laboratory of Particle Detection and Electronics Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China Dongguan Songshan Lake Future School Dongguan 523808China North Night Vision Science&Technology(Nanjing)Research Institute Co.Ltd. Nanjing 211106China Sino‑French Institute of Nuclear Engineering and Technology Sun Yat-sen UniversityZhuhai 519082China School of Nuclear Science and Technology University of Science and Technology of ChinaHefei 230027China State Key Laboratory of Particle Detection and Electronics University of Science and Technology of ChinaHefei 230026China Department of Modern Physics University of Science and Technology of ChinaHefei 230026China State Key Laboratory of Nuclear Physics and Technology School of PhysicsPeking UniversityBeijing 100871China Institute of Nuclear Physics and Chemistry China Academy of Engineering PhysicsMianyang 621900China Key Laboratory of Nuclear Data China Institute of Atomic EnergyBeijing 102413China USTC Archaeometry Lab University of Science and Technology of ChinaHefei 230026China Northwest Institute of Nuclear Technology Xi’an 710024China University of Chinese Academy of Sciences Beijing 100049China

Neutron-sensitive microchannel plates(nMCPs)have applications in neutron detection,including energy spectrum measurements,neutron-induced cross sections,and neutron imaging.10B-doped MCPs(B-MCPs)have attracted significant attention owing to their potential for exhibiting a high neutron detection efficiency over a large neutron energy *** spatial and temporal resolutions are useful for neutron energy-resolved ***,their practical applications still face many technical *** this study,a B-MCP with 10 mol%10B was tested for its response to wide-energy neutrons from eV to MeV at the Back-n white neutron source at the China Spallation Neutron *** neutron detection efficiency was calibrated at 1 eV,which is approximately 300 times that of an ordinary MCP and indicates the success of 10 B *** factors that caused the reduction in the detection efficiency were simulated and *** neutron energy spectrum obtained using B-MCP was compared with that obtained by other measurement methods,and showed very good consistency for neutron energies below tens of *** response is more complicated at higher neutron energy,at which point the elastic and nonelastic reactions of all nuclides of B-MCP gradually become *** is beneficial for the detection of neutrons,as it compensates for the detection efficiency of B-MCP for high-energy neutrons.

关键词： Neutron radiation image 10B-doped MCP Neutron response Wide-energy range neutrons

Nondestructive technique for identifying nuclides using neutron resonance transmission analysis at CSNS Back-n

在线全文

学校读者我要写书评

暂无评论

Nuclear Science and Techniques 2024年第1期35卷 178-187页

作者： Sheng-Da Tang Yong-Hao Chen Jing-Yu Tang Rui-Rui Fan Qiang li Gong li Dong liu Zheng-Yao Jin Xing-Zhu Cui Tian-Xiang Chen Yi-Wei yang Rong liu Han Yi yang li Zhen yang Qi An Hao-Fan Bai Jiang-Bo Bai jie Bao Ping Cao Qi-Ping Chen Zhen Chen Zeng-Qi Cui An-Chuan Fan Chang-Qing Feng Fan-Zhen Feng Ke-Qing Gao Min-Hao Gu Chang-Cai Han Zi-jie Han Guo-Zhu He Yong-Cheng He yang Hong Yi-Wei Hu Han-Xiong huang Wei-hua Jia Hao-yu Jiang Wei Jiang Zhi-jie Jiang ling Kang Bo li Chao li Jia-Wen li Xiao li jie liu Shu-bin liu guang-Yuan luan Chang-jun ning bin-bin Qi jie Ren Zhi-Zhou Ren Xi-Chao Ruan zhao-Hui Song Kang Sun Zhi-Xin Tan li-Jiao Wang Peng-Cheng Wang zhao-Hui Wang Zhong-Wei Wen Xiao-guang Wu Xuan Wu li-Kun Xie Yong-Ji Yu Guo-Hui zhang lin-Hao zhang Mo-Han zhang Qi-Wei zhang Xian-Peng zhang Yu-liang zhang Yue zhang Zhi-Yong zhang Mao-Yuan zhao lu-Ping Zhou Zhi-Hao Zhou Ke-jun Zhu Sino-French Institute of Nuclear Engineering and Technology Sun Yat-sen UniversityZhuhai 519082China Institute of High-Energy Physics Chinese Academy of Sciences(CAS)Beijing 100049China Spallation Neutron Source Science Center Dongguan 523803China School of Nuclear Science and Technology University of Science and Technology of ChinaHefei 230026China State Key Laboratory of Particle Detection and Electronics University of Science and Technology of ChinaHefei 230026China State Key Laboratory of Particle Detection and Electronics Institute of High Energy PhysicsChinese Academy of SciencesBeijing 100049China USTC Archaeometry Laboratory University of Science and Technology of ChinaHefei 230026China Institute of Nuclear Physics and Chemistry China Academy of Engineering PhysicsMianyang 621900China Department of Modern Physics University of Science and Technology of ChinaHefei 230026China State Key Laboratory of Nuclear Physics and Technology School of PhysicsPeking UniversityBeijing 100871China Key Laboratory of Nuclear Data China Institute of Atomic EnergyBeijing 102413China Northwest Institute of Nuclear Technology Xi’an 710024China University of Chinese Academy of Sciences Beijing 100049China

Nondestructive and noninvasive neutron assays are essential applications of neutron *** resonance transmission analysis(NRTA)is a powerful nondestructive method for investigating the elemental composition of an *** back-streaming neutron line(Back-n)is a newly built time-of-flight facility at the China Spallation Neutron Source(CSNS)that provides neutrons in the eV to 300 MeV range.A feasibility study of the NRTA method for nuclide identification was conducted at the CSNS Back-n via two test *** results demonstrate that it is feasible to identify different elements and isotopes in samples using the NRTA method at *** study reveals its potential future applications.

关键词： CSNS White neutron beam NRTA Nuclide identification Nondestructive method

在线全文

学校读者我要写书评

暂无评论

成人多囊肝病临床分期对治疗方式选择的价值

第二军医大学学报 2009年第6期30卷 676-679页

作者：张海斌李团结杨宁卢军华赵军司马辉杨广顺第二军医大学东方肝胆外科医院胆道二科上海200438 中山大学附属第三医院肝移植中心广州510630

目的:探讨成人多囊肝病(APLD)的临床分期对治疗方式选择的指导意义。方法:回顾分析我院自1995年5月～2007年10月间共收治的43例APLD患者的临床资料,根据临床表现及影像学检查将其分为3期:无症状或轻微症状期、明显症状期、致死症状期。2... 详细信息

目的:探讨成人多囊肝病(APLD)的临床分期对治疗方式选择的指导意义。方法:回顾分析我院自1995年5月～2007年10月间共收治的43例APLD患者的临床资料,根据临床表现及影像学检查将其分为3期:无症状或轻微症状期、明显症状期、致死症状期。26例接受肝部分切除联合广泛囊肿开窗术治疗,17例门诊随访观察。结果:15例门诊随访无症状或轻微症状期患者,其中1例合并原发性肝癌,发病后4个月死亡;其余14例平均随访(42.8±37.9)个月,12例病程进展缓慢,2例病情发展较快,后接受手术治疗。24例明显症状期患者接受肝部分切除联合囊肿广泛开窗术治疗,无围手术期死亡,平均随访(61.4±43.0)个月,2例死于肾功能衰竭,3例术后症状复发。4例致死症状期患者,2例接受肝部分切除联合广泛囊肿开窗术治疗,其中1例术后症状无缓解,1例术后发生肝功能不全,于术后8个月接受肝移植治疗;2例门诊接受经皮穿刺抽液治疗,1例随访5个月后死于上消化道出血,1例接受经皮穿刺抽液治疗后症状稍缓解。结论:成人多囊肝病的临床分期有助于患者治疗方式的选择:无症状或轻微症状期患者一般可临床随访;明显症状期患者可采用手术治疗;致死症状期患者不宜接受常规手术治疗,可能需行肝移植。

关键词：成人多囊肝病分期肝切除术开窗术

Inverted U-Shaped Associations between Glycemic Indices and Serum Uric Acid Levels in the General Chinese Population:Findings from the China Cardiometabolic Disease and Cancer Cohort(4C)Study

在线全文

学校读者我要写书评

暂无评论

Biomedical and Environmental Sciences 2021年第1期34卷 9-18页

作者： ZHU Yuan Yue ZHENG Rui Zhi WANG Gui Xia CHEN li SHI li Xin SU Qing XU Min XU Yu CHEN Yu Hong YU Xue Feng YAN li WANG Tian Ge zhao Zhi Yun QIN Gui jun WAN Qin CHEN Gang GAO Zheng Nan SHEN Fei Xia luO Zuo jie QIN Ying Fen HUO Ya Nan li Qiang YE Zhen zhang Yin Fei liU Chao WANG You Min WU Sheng li yang Tao DENG hua Cong zhao Jia jun CHEN lu lu MU Yi Ming TANG Xu Lei HU Ru Ying WANG Wei Qing ning guang li Mian lu jie li BI Yu Fang Department of Endocrine and Metabolic Diseases Shanghai Institute of Endocrine and Metabolic DiseasesRuijin HospitalShanghai Jiao Tong University School of MedicineShanghai 200025China Shanghai National Clinical Research Center for Metabolic Diseases Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR ChinaShanghai National Center for Translational MedicineRuijin Hospital.Shanghai Jiao Tong UniversitySchool of MedicineShanghai 200025China The First Hospital of Jilin University Changchun 130021JinlinChina Qilu Hospital of Shandong University Jinan 250012ShandongChina Affiliated Hospital of Guiyang Medical College Guiyang 550004GuizhouChina Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine Shanghai 200092China Tongji Hospital.Tongji Medical College Huazhong University of Science and TechnologyWuhan 430030HubeiChina Sun Yat-sen Memorial Hospital Sun Yat-sen UniversityGuangzhou 510120GuangdongChina The First Affiliated Hospital of Zhengzhou University Zhengzhou 450052HenanChina The Affiliated Hospital of Southwest Medical University Luzhou 646099SichuanChina Fujian Provincial Hospital Fujian Medical UniversityFuzhou 350001FujianChina Dalian Municipal Central Hospital Dalian 116003LiaoningChina The First Affiliated Hospital of Wenzhou Medical University Wenzhou 325000ZhejiangChina The First Affiliated Hospital of guangxi Medical University Nanning 530021GuangxiChina Jiangxi Provincial People's Hospital Affiliated to Nanchang University Nanchang 330006JiangxiChina The Second Affiliated Hospital of Harbin Medical University Harbin 150086HeilongjiangChina Zhejiang Provincial Center for Disease Control and Prevention Hangzhou 310051ZhejiangChina Central Hospital of Shanghai Jiading District Shanghai 201800China Jiangsu Province Hospital on Integration of Chinese and Western Medicine Nanjing 210028JiangsuChina The First Affiliated Hospital of Anhui Medical University Hefei 230022AnhuiChina Karamay Municipal

Objective The relationship between serum uric acid(SUA)levels and glycemic indices,including plasma glucose(FPG),2-hour postload glucose(2 h-PG),and glycated hemoglobin(HbA1 c),remains *** aimed to explore the associations between glycemic indices and SUA levels in the general Chinese *** The current study was a cross-sectional analysis using the first follow-up survey data from The China Cardiometabolic Disease and Cancer Cohort Study.A total of 105,922 community-dwelling adults aged≥40 years underwent the oral glucose tolerance test and uric acid *** nonlinear relationships between glycemic indices and SUA levels were explored using generalized additive *** A total of 30,941 men and 62,361 women were eligible for the current *** additive models verified the inverted U-shaped association between glycemic indices and SUA levels,but with different inflection points in men and *** thresholds for FPG,2 h-PG,and HbA1 c for men and women were 6.5/8.0 mmol/L,11.0/14.0 mmol/L,and 6.1/6.5,respectively(SUA levels increased with increasing glycemic indices before the inflection points and then eventually decreased with further increases in the glycemic indices).Conclusion An inverted U-shaped association was observed between major glycemic indices and uric acid levels in both sexes,while the inflection points were reached earlier in men than in women.

关键词： Cross-sectional study Serum uric acid Glycemic index Glycemic status

Efficacy and safety of sirolimus early conversion protocol in liver transplant patients with hepatocellular carcinoma:A single-arm, multicenter, prospective study

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary & Pancreatic Diseases International 2022年第2期21卷 106-112页

作者： Ren-Yi Su Sun-bin ling Qiao-Nan Shan Xu-Yong Wei Rui Wang Chang-Ku Jia li Zhuang Tian Shen li-Min Ding Zhi-Dan Xu Lai-Bang luo li-Bo Sun guang-Ming li Tai-Shi Fang Nan Jiang Kun zhang zhao-jie Su Zhi-hai Peng Ren Lang Tao Jiang Qiang He lin-Sen Ye yang yang Yu-Ting He Wen-Zhi Guo liu-Gen Lan Xu-Yong Sun Dong Chen Zhi-Shui Chen Da-Wei Zhou Shao-jun Ye Qi-Fa Ye Min Tian Jian-hua Shi Bo Wang Jiang liu Qian lu Wei Rao Jin-Zhen Cai Tao Lv Jia-Yin yang Pu-Sen Wang lin Zhong Jing-Sheng Ma Qi-Gen li Sheng-Dong Wu Chang-Jiang lu Cai-De lu Dong-hua zhang Xuan Wang Zi-Qiang li Mu-Jian Teng jun-jie li Wen-Tao Jiang Jian-hua li Quan-Bao zhang ning-Qi Zhu Zheng-Xin Wang Kang He Qiang Xia Shao-hua Song Zhi-Ren Fu Wei Qiu Guo-Yue Lv Rui-Peng Song Ji-Zhou Wang Zheng Wang Jian Zhou Gang Chen Ying-Peng zhao li li Ze-Min Hu Qi-jie luo Zhong-Zhou Si bin Xie Xiao-shun He Zhi-Yong Guo Shu-Sen Zheng Xiao Xu Department of Hepatobiliary and Pancreatic Surgery The Center for Integrated Oncology and Precision MedicineAffiliated Hangzhou First People’s HospitalZhejiang University School of MedicineHangzhou 310006China NHC Key Laboratory of Combined Multi-organ Transplantation Hangzhou 310003China Department of Hepatobiliary and Pancreatic Surgery Shulan(Hangzhou)HospitalZhejiang Shuren University School of MedicineHangzhou 310022China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated HospitalZhejiang University School of MedicineHangzhou 310003China Department of Transplantation Jiangxi Provincial People’s Hospital Affiliated to Nanchang UniversityNanchang 330006China liver Transplantation Center Beijing You’an HospitalCapital Medical UniversityBeijing 100069China Department of Hepatic Surgery National Clinical Research Center for Infectious DiseaseShenzhen Third People’s HospitalThe Second Affiliated Hospital of Southern University of Science and TechnologyShenzhen 518112China Department of General Surgery Xiang’an Hospital of Xiamen UniversityXiamen 361000China Deartment of Hepatobiliary and Pancreaticosplenic Surgery Beijing Chaoyang HospitalCapital Medical UniversityBeijing 100020China Department of Hepatic Surgery and liver Transplantation Center The Third Affiliated Hospital of Sun Yat-sen UniversityGuangzhou 510630China Department of Hepatobiliary and Pancreatic Surgery The First Affiliated Hospital of Zhengzhou UniversityZhengzhou 450052China Department of liver Transplantation The Second Affiliated Hospital of Guangxi Medical UniversityNanning 530000China Institute of Organ Transplantation Tongji HospitalTongji Medical CollegeHuazhong University of Science and TechnologyWuhan 430030China Institute of Hepatobiliary Diseases of Wuhan University Transplant Center of Wuhan UniversityHubei Key Laboratory of Medical Technology on TransplantationZhongnan Hospital of Wuhan UniversityWuhan 430071China Department of Hepatobiliary Surgery The First Affiliated Hos

Mammalian target of rapamycin(m TOR) inhibitor as an attractive drug target with promising antitumor effects has been widely investigated. High quality clinical trial has been conducted in liver transplant(LT) recipients in Western countries. However, the pertinent studies in Eastern world are paucity. Therefore, we designed a clinical trial to test whether sirolimus can improve recurrence-free survival(RFS) in hepatocellular carcinoma(HCC) patients beyond the Milan criteria after LT. This is an open-labeled, single-arm, prospective, multicenter, and real-world study aiming to evaluate the clinical outcomes of early switch to sirolimus-based regimens in HCC patients after LT. Patients with a histologically proven HCC and beyond the Milan criteria will be enrolled. The initial immunosuppressant regimens are center-specifc for the frst 4-6 weeks. The following regimens integrated sirolimus into the regimens as a combination therapy with reduced calcineurin inhibitors based on the condition of patients and centers. The study is planned for 4 years in total with a 2-year enrollment period and a 2-year follow-up. We predict that sirolimus conversion regimen will provide survival benefts for patients particular in the key indicator RFS as well as better quality of life. If the trial is conducted successfully, we will have a continued monitoring over a longer follow-up time to estimate indicator of overall survival. We hope that the outcome will provide better evidence for clinical decision-making and revising treatment guidelines based on Chinese population data.

关键词： Sirolimus Immunosuppressive agents Hepatocellular carcinoma liver transplantation Conversion

The first data release(DR1) of the LAMOST regular survey

在线全文

学校读者我要写书评

暂无评论

Research in Astronomy and Astrophysics 2015年第8期15卷 1095-1124页

作者： A-li luo Yong-Heng zhao Gang zhao li-Cai Deng Xiao-Wei liu Yi-Peng Jing Gang Wang Hao-Tong zhang Jian-Rong Shi Xiang-Qun Cui Yao-Quan Chu Guo-Ping li Zhong-Rui Bai Yue Wu Yan Cai Shu-Yun Cao Zi-huang Cao Jeffrey L.Carlin hai-Yuan Chen Jian-jun Chen Kun-Xin Chen li Chen Xue-Lei Chen Xiao-Yan Chen Ying Chen Norbert Christlieb Jia-Ru Chu Chen-Zhou Cui Yi-Qiao Dong bing Du Dong-Wei Fan Lei Feng Jian-ning Fu Peng Gao Xue-Fei Gong Bo-Zhong Gu Yan-Xin Guo Zhan-Wen Han Bo-liang He Jin-liang Hou Yong-Hui Hou Wen Hou Hong-Zhuan Hu ning-Sheng Hu Zhong-Wen Hu Zhi-Ying Huo Lei Jia Fang-hua Jiang Xiang Jiang Zhi-Bo Jiang Ge Jin Xiao Kong Xu Kong Ya-Juan Lei Ai-hua li Chang-hua li guang-Wei li hai-ning li Jian li Qi li Shuang li Sha-Sha li Xin-Nan li Yan li Yin-Bi li Ye-Ping li Yuan liang Chien-Cheng lin Chao liu Gen-Rong liu Guan-Qun liu Zhi-Gang liu Wen-Zhi lu Yu luo Yin-Dun Mao Heidi Newberg Ji-jun Ni zhao-Xiang Qi Yong-jun Qi Shi-Yin Shen Huo-Ming Shi Jing Song Yi-Han Song Ding-Qiang Su Hong-jun Su Zheng-Hong Tang Qing-Sheng Tao Yuan Tian Dan Wang Da-Qi Wang Feng-Fei Wang Guo-Min Wang hai Wang Hong-Chi Wang Jian Wang Jia-ning Wang Jian-ling Wang Jian-Ping Wang jun-Xian Wang Lei Wang Meng-Xin Wang Shou-Guan Wang Shu-Qing Wang Xia Wang Ya-Nan Wang You Wang Yue-Fei Wang You-Fen Wang Peng Wei Ming-Zhi Wei Hong Wu Ke-Fei Wu Xue-bing Wu Yu-Zhong Wu Xiao-Zheng Xing ling-Zhe Xu Xin-Qi Xu Yan Xu Tai-Sheng Yan De-hua yang hai-Feng yang Hui-Qin yang Ming yang Zheng-Qiu Yao Yong Yu Hui Yuan hai-Bo Yuan hai-Long Yuan Wei-Min Yuan Chao Zhai En-Peng zhang hua-Wei zhang Jian-Nan zhang li-Pin zhang Wei zhang Yong zhang Yan-Xia zhang Zheng-Chao zhang Ming zhao Fang Zhou Xu Zhou jie Zhu Yong-Tian Zhu Si-Cheng Zou Fang Zuo National Astronomical Observatories Chinese Academy of Sciences Department of Astronomy Peking University Shanghai Astronomical Observatory Chinese Academy of Sciences Nanjing Institute of Astronomical Optics & Technology National Astronomical ObservatoriesChinese Academy of Sciences University of Science and Technology of China Department of Physics Applied Physics and AstronomyRensselaer Polytechnic InstituteTroyNY 12180USA Department of Physics and Astronomy Earlham CollegeRichmondIN 47374USA Universitt Heidelberg Zentrum für AstronomieLandessternwarteKnigstuhl 1269117 HeidelbergGermany Department of Astronomy Beijing Normal University Yunnan Observatories Chinese Academy of Sciences Purple Mountain Observatory Chinese Academy of Sciences

The Large sky Area Multi-Object Fiber Spectroscopic Telescope（LAMOST） general survey is a spectroscopic survey that will eventually cover approximately half of the celestial sphere and collect 10 million spectra of stars, galaxies and QSOs. Objects in both the pilot survey and the first year regular survey are included in the LAMOST DR1. The pilot survey started in October 2011 and ended in june 2012, and the data have been released to the public as the LAMOST Pilot Data Release in August 2012. The regular survey started in September 2012, and completed its first year of operation in june 2013. The LAMOST DR1 includes a total of 1202 plates containing 2 955 336 spectra, of which 1 790 879 spectra have observed signalto-noise ratio（SNR） ≥ 10. All data with SNR ≥ 2 are formally released as LAMOST DR1 under the LAMOST data policy. This data release contains a total of 2 204 696 spectra, of which 1 944 329 are stellar spectra, 12 082 are galaxy spectra and 5017 are quasars. The DR1 not only includes spectra, but also three stellar catalogs with measured parameters： late A,FGK-type stars with high quality spectra（1 061 918 entries）, A-type stars（100 073 entries）, and M-type stars（121 522 entries）. This paper introduces the survey design, the observational and instrumental limitations, data reduction and analysis, and some caveats. A description of the FITS structure of spectral files and parameter catalogs is also provided.

关键词： techniques: spectroscopic survey—data release—catalog

Efficacy and safety of Shenyankangfu Tablet,a Chinese patent medicine,for primary glomerulonephritis:A multicenter randomized controlled trial

在线全文

学校读者我要写书评

暂无评论

Journal of Integrative Medicine 2021年第2期19卷 111-119页

作者： jie Wu Shu-wei Duan Hong-tao yang Yue-yi Deng Wei li Ya-ni He zhao-hui Ni Yong-li Zhan Shan lin Zhi-yong Guo jun Zhu Jing-ai Fang Xu-sheng liu li-hua Wang Rong Wang Nian-song Wang Xiao-hong Cheng li-qun He Ping luo Shi-ren Sun Ji-feng Sun Ai-ping Yin Geng-ru Jiang Hong-yu Chen Wen-hu liu Hong-li lin Meng liang lu Ma Ming Chen li-qun Song Jian Chen Qing Zhu Chang-ying Xing Yun li Ji-ning Gao Rong-shan li Ying li Hao zhang Ying lu Qiao-ling Zhou jun-zhou Fu Qiang He guang-yan Cai Xiang-mei Chen Department of Nephrology Chinese People’s Liberation Army General HospitalChinese People’s Liberation Army Institute of NephrologyState Key Laboratory of Kidney Diseases(2011DAV00088)National Clinical Research Center for Kidney DiseasesBeijing 100853China Department of Nephrology First Teaching Hospital of Tianjin University of Traditional Chinese MedicineTianjin 300192China Department of Nephrology Longhua HospitalShanghai University of Traditional Chinese MedicineShanghai 200032China Department of Nephrology Shandong University of Traditional Chinese Medicine Affiliated HospitalJinan 250011.Shandong ProvinceChina Department of Nephrology Daping HospitalArmy Medical UniversityChongqing 400042China Department of Nephrology Renji HospitalShanghai Jiao Tong UniversityShanghai 200127China Department of Nephrology Guang’anmen HospitalChina Academy of Traditional Chinese Medical SciencesBeijing 100053China Department of Nephrology Tianjin Medical University General HospitalTianjin 300052China Department of Nephrology Changhai Hospital of ShanghaiNaval Medical UniversityShanghai 200433China Department of Nephrology West China HospitalChengdu 610083Sichuan ProvinceChina Department of Nephrology First Affiliated Hospital of Shanxi Medical UniversityTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Guangdong Provincial Hospital of Chinese MedicineGuangzhou 510120Guangdong ProvinceChina Department of Nephrology Shanxi Medical University Second Affiliated HospitalTaiyuan 030001Shanxi ProvinceChina Department of Nephrology Shandong Provincial HospitalJinan 250021Shandong ProvinceChina Department of Nephrology and Rheumatology Affiliated Sixth People’s HospitalShanghai Jiao Tong UniversityShanghai 200233China Department of Nephrology Shaanxi Traditional Chinese Medicine HospitalXi'an 710003Shaanxi ProvinceChina Department of Nephrology Shuguang HospitalShanghai University of Traditional Chinese MedicineShanghai 200021China Department of Nephrology Jilin University Se

Background:Shenyankangfu Tablet(SYKFT)is a Chinese patent medicine that has been used widely to decrease proteinuria and the progression of chronic kidney ***:This trial compared the efficacy and safety of SYKFT,for the control of proteinuria in primary glomerulonephritis patients,against the standard drug,losartan ***,setting,participants and intervention:This was a multicenter,double-blind,randomized,controlled clinical *** glomerulonephritis patients,aged 18-70 years,with blood pressure≤140/90 mmHg,estimated glomerular filtration rate(eGFR)>45 mL/min per 1.73 ㎡,and 24-hour proteinuria level of 0.5-3.0 g,were recruited in 41 hospitals across 19 provinces in China and were randomly divided into five groups:SYKFT,losartan potassium 50 mg or 100 mg,SYKFT plus losartan potassium 50 mg or 100 *** outcome measu res:The primary outcome was change in the 24-hour proteinuria level,after 48 weeks of ***:A total of 735 participants were *** percent decline of urine protein quantification in the SYKFT group after 48 weeks was 8.78%±2.56%(P=0.006)more than that in the losartan 50 mg group,which was 0.51%±2.54%(P=1.000)less than that in the losartan 100 mg *** with the losartan potassium 50 mg group,the SYKFT plus losartan potassium 50 mg group had a 13.39%±2.49%(Plus losartan potassium 100 mg group had a 9.77%±2.52%(P=0.001)greater reduction in urine *** a superiority threshold of 15%,neither was statistically ***,serum creatinine and serum albumin from the baseline did not change statistically *** average change in TCM syndrome score between the patients who took SYKFT(-3.00[-6.00,-2.00])and who did not take SYKFT(-2.00[-5.00,0])was statistically significant(P=0.003).No obvious adverse reactions were observed in any ***:SYKFT decreased the proteinur

关键词： Herbal medicine,Chinese Shenyankangfu Tablet Primary glomerulonephritis Randomized controlled trial Double blind Double dummy

Searching for ^(76)Ge neutrinoless double beta decay with the CDEX-1B experiment

在线全文

学校读者我要写书评

暂无评论

Chinese Physics C 2024年第10期48卷 11-22页

作者： bing-Tao zhang jun-Zheng Wang li-Tao yang Qian Yue Ke-jun Kang Yuan-Jing li hai-Peng An C.Greeshma Jian-Ping Chang Yun-huan Chen Jian-Ping Cheng Wen-Han Dai Zhi Deng Chang-Hao Fang Xin-Ping Geng Hui Gong Qiu-Ju Guo Xu-Yuan Guo li He Sheng-Ming He Jin-Wei Hu Han-Xiong huang Tu-Chen huang hai-Tao Jia Xi Jiang S.Karmakar Hao-bin li Jian-Min li Jin li Qian-Yun li Ren-Ming-jie li Xue-Qian li Yu-Lan li Yi-Fan liang bin liao Fong-Kay lin Shin-Ted lin Jia-Xuan liu Shu-Kui liu Yan-Dong liu Yu liu Yuan-Yuan liu Zhong-Zhi liu Hao Ma Yu-Cai Mao Qi-Yuan Nie Jin-hua ning Hui Pan ning-Chun Qi jie Ren Xi-Chao Ruan Ze She Manoj Kumar Singh Tian-Xi Sun Chang-Jian Tang Wei-You Tang yang Tian guang-Fu Wang li Wang Qing Wang Yu-Feng Wang Yun-Xiang Wang Henry-Tsz-King Wong Shi-Yong Wu Yu-Cheng Wu Hao-yang Xing Rui Xu Yin Xu Tao Xue Yu-lu Yan Nan Yi Chun-Xu Yu hai-jun Yu Jian-Feng Yue Ming Zeng Zhi Zeng Feng-Shou zhang Lei zhang Zhen-hua zhang Zhen-Yu zhang Kang-Kang zhao Ming-Gang zhao Ji-Fang Zhou Zu-Ying Zhou Jing-jun Zhou Key Laboratory of Particle and Radiation Imaging(Ministry of Education)and Department of Engineering Physics Tsinghua UniversityBeijing 100084 Department of Physics Tsinghua UniversityBeijing 100084 Institute of Physics Academia SinicaTaipei 11529 NUCTECH Company Beijing 100084 YaLong River Hydropower Development Company Chengdu 610051 College of Nuclear Science and Technology Beijing Normal UniversityBeijing 100875 College of Physics Sichuan UniversityChengdu 610065 School of Physics Peking UniversityBeijing 100871 Department of Nuclear Physics China Institute of Atomic EnergyBeijing 102413 Sino-French Institute of Nuclear and Technology Sun Yat-sen UniversityZhuhai 519082 School of Physics Nankai UniversityTianjin 300071 Department of Physics Banaras Hindu UniversityVaranasi 221005 Department of Physics Beijing Normal UniversityBeijing 100875

We operated a p-type point contact high purity germanium(PPCGe)detector(CDEX-1B,1.008 kg)in the China Jinping Underground Laboratory(CJPL)for 500.3 days to search for neutrinoless double beta(0νββ)decay of ^(76)Ge.A total of 504.3 kg⋅day effective exposure data was *** anti-coincidence and the multi/single-site event(MSE/SSE)discrimination methods were used to suppress the background in the energy region of interest(ROI,1989–2089 keV for this work)with a factor of 23.A background level of 0.33 counts/(keV⋅kg⋅yr)was *** lower limit on the half life of^(76)Ge 0νββdecay was constrained as T_(1/2)^(0ν)>1.0×10^(23)yr(90%C.L.),corresponding to the upper limits on the effective Majorana neutrino mass:<3.2–7.5 eV.

关键词： neutrinoless double beta decay CDEX point-contact germanium detector ^(76)Ge